Funding Announcement: AVAIL Secures $5 Million in Pre-Seed Round for Life Sciences Innovation Advancement

AVAIL is excited to announce that it has successfully raised $5 million in a recent funding round, a significant step in its mission to drive forward groundbreaking innovations in life sciences. The AVAIL Global Network consists of a dedicated group of R&D-performing and consulting organizations, including the Avail Biomedical Research Institute and Avail Pharma, all committed to advancing viable, applicable innovations in health care. The funds raised will be instrumental in enhancing the capabilities of its GMP- and GLP-compliant research facilities, facilitating the execution of in-house projects, and providing unparalleled logistical and scientific support for collaborative research. With a special focus on optimizing pulmonary disease models, in-vitro tissue engineering, and drug testing, this funding will accelerate critical areas of research that hold the promise of transforming patient outcomes. In addition, the strategic counseling services provided by Avail Pharma will further evolve, enabling the company to enhance the commercial viability of emerging projects and drive the translation of research breakthroughs into market-ready solutions. The team at AVAIL is deeply grateful to our investors for their confidence in our vision of revolutionizing life sciences, and we are eager to harness these resources in our ongoing mission to foster innovation and improve patient care. As we move forward, we remain dedicated to creating impactful solutions that benefit patients worldwide.